INTRODUCTION: It has been postulated that the prevalence of polycystic ovary syndrome (PCOS) in female-to-male transsexuals (FMTs) is higher than normal. AIM: The aim of the study was to investigate the prevalence of PCOS and hyperandrogenemia in FMTs, compared with controls. METHODS: Sixty-one FMTs were evaluated using the Rotterdam 2003 criteria and National Institutes of Health 1990 criteria for the diagnosis of PCOS, compared with 94 controls. MAIN OUTCOME MEASURE(S): Oligoovulation, anovulation, clinical and biochemical signs of hyperandrogenism and polycystic ovaries, and prevalence of PCOS were measured. RESULTS: The prevalence of PCOS was 11.5% in FMTs and 9.6% in controls (not significant) with National Institutes of Health 1990 criteria and 14.8% in FMTs and 12.8% in controls (not significant) with the Rotterdam 2003 criteria. Without adjustments and using multivariate analysis in a logistic regression model with adjustments for age, body mass index, and calculated free testosterone, the odds ratio for the prevalence of PCOS was not found to be significantly increased. However, there was a significantly higher prevalence of biochemical hyperandrogenism in FMTs. Hyperandrogenemia was associated with a moderate increase in the odds ratio for the prevalence of PCOS, at 1.08 and 1.07 (P < 0.001 and P = 0.001), for the two definitions used in this study, respectively. CONCLUSIONS: PCOS was not significantly increased in FMTs in comparison with controls. However, FMTs more frequently had biochemical hyperandrogenism.
INTRODUCTION: It has been postulated that the prevalence of polycystic ovary syndrome (PCOS) in female-to-male transsexuals (FMTs) is higher than normal. AIM: The aim of the study was to investigate the prevalence of PCOS and hyperandrogenemia in FMTs, compared with controls. METHODS: Sixty-one FMTs were evaluated using the Rotterdam 2003 criteria and National Institutes of Health 1990 criteria for the diagnosis of PCOS, compared with 94 controls. MAIN OUTCOME MEASURE(S): Oligoovulation, anovulation, clinical and biochemical signs of hyperandrogenism and polycystic ovaries, and prevalence of PCOS were measured. RESULTS: The prevalence of PCOS was 11.5% in FMTs and 9.6% in controls (not significant) with National Institutes of Health 1990 criteria and 14.8% in FMTs and 12.8% in controls (not significant) with the Rotterdam 2003 criteria. Without adjustments and using multivariate analysis in a logistic regression model with adjustments for age, body mass index, and calculated free testosterone, the odds ratio for the prevalence of PCOS was not found to be significantly increased. However, there was a significantly higher prevalence of biochemical hyperandrogenism in FMTs. Hyperandrogenemia was associated with a moderate increase in the odds ratio for the prevalence of PCOS, at 1.08 and 1.07 (P < 0.001 and P = 0.001), for the two definitions used in this study, respectively. CONCLUSIONS:PCOS was not significantly increased in FMTs in comparison with controls. However, FMTs more frequently had biochemical hyperandrogenism.
Authors: Smita C Banerjee; Jessica M Staley; Koshy Alexander; Chasity B Walters; Patricia A Parker Journal: Transl Behav Med Date: 2020-10-08 Impact factor: 3.046
Authors: H M Kinnear; E S Constance; A David; E E Marsh; V Padmanabhan; A Shikanov; M B Moravek Journal: Hum Reprod Date: 2019-10-02 Impact factor: 6.918
Authors: Kate Millington; Caroline Schulmeister; Courtney Finlayson; Ren Grabert; Johanna Olson-Kennedy; Robert Garofalo; Stephen M Rosenthal; Yee-Ming Chan Journal: J Adolesc Health Date: 2020-05-14 Impact factor: 5.012
Authors: Rebecca M Jones; Sally Wheelwright; Krista Farrell; Emma Martin; Richard Green; Domenico Di Ceglie; Simon Baron-Cohen Journal: J Autism Dev Disord Date: 2012-02